Prevention of infection due to Pneumocystis carinii.
Fishman
J A
JA
Infectious Disease Unit, Massachusetts General Hospital and Harvard Medical School, Boston 02114, USA. jfishman@helix.mgh.harvard.edu
D000818:Animals; D019072:Antibiotic Prophylaxis; D000935:Antifungal Agents / Q000627:therapeutic use*; D053626:Atovaquone; D002981:Clindamycin / Q000627:therapeutic use; D003622:Dapsone / Q000627:therapeutic use; D005657:Fungal Vaccines / Q000008:administration & dosage; D006801:Humans; D008826:Microbial Sensitivity Tests; D009285:Naphthoquinones / Q000627:therapeutic use; D010419:Pentamidine / Q000627:therapeutic use; D011010:Pneumocystis / Q000254:growth & development / Q000276:immunology; D011020:Pneumonia, Pneumocystis / Q000517:prevention & control*; D011739:Pyrimethamine / Q000627:therapeutic use; D015662:Trimethoprim, Sulfamethoxazole Drug Combination / Q000627:therapeutic use
D000935:Antifungal Agents; D005657:Fungal Vaccines; D009285:Naphthoquinones; D002981:Clindamycin; D010419:Pentamidine; D015662:Trimethoprim, Sulfamethoxazole Drug Combination; D003622:Dapsone; D053626:Atovaquone; D011739:Pyrimethamine